Added to YB: 2026-07-21
Pitch date: 2026-07-17
POLB.L [neutral]
Poolbeg Pharma PLC
Author Info
No bio for this author
Company Info
Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, engages in developing immunotherapy for cancer in the United Kingdom.
Market Cap
GBP 43.4M
Pitch Price
GBP 0.06
Price Target
N/A
Dividend
N/A
EV/EBITDA
-5.68
P/E
-6.51
EV/Sales
N/A
Sector
Pharmaceuticals
Category
growth
Poolbeg Pharma PLC - $POLB.L
POLB.L (overview): UK biotech, £44M mkt cap, developing POLB 001, oral p38 MAPK inhibitor to prevent Cytokine Release Syndrome (affects 70%+ CAR-T/bispecific patients). Platform-agnostic supportive-care play; peer-reviewed data, FDA Orphan status, J&J supplies free drug. TOPICAL interim data late summer '26 key catalyst. $10B+ TAM, cash to Q2'28. Partnering-focused exit. Risky biotech.
Read full article (19 min)